Complement component 5 is the fifth component of complement, which plays an important role in inflammatory and cell killing processes. This protein is composed of alpha and beta polypeptide chains that are linked by a disulfide bridge. An activation peptide, C5a, which is an anaphylatoxin that possesses potent spasmogenic and chemotactic activity, is derived from the alpha polypeptide via cleavage with a C5-convertase. The C5b macromolecular cleavage product can form a complex with the C6 complement component, and this complex is the basis for formation of the membrane attack complex, which includes additional complement components.[1]
Clinical significance
Mutations in this gene cause complement component 5 deficiency, a disease where patients show a propensity for severe recurrent infections. Defects in this gene have also been linked to a susceptibility to liver fibrosis and to rheumatoid arthritis.[1]
Therapeutic applications
The drug eculizumab (trade name Soliris) prevents cleavage of C5 into C5a and C5b.[3]
Tack BF, Morris SC, Prahl JW (1979). "Fifth component of human complement: purification from plasma and polypeptide chain structure". Biochemistry. 18 (8): 1490–7. doi:10.1021/bi00575a016. PMID106884.
Fernandez HN, Hugli TE (1978). "Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a". J. Biol. Chem. 253 (19): 6955–64. PMID690134.
DiScipio RG (1992). "Formation and structure of the C5b-7 complex of the lytic pathway of complement". J. Biol. Chem. 267 (24): 17087–94. PMID1387399.
Haviland DL, Haviland JC, Fleischer DT, et al. (1991). "Complete cDNA sequence of human complement pro-C5. Evidence of truncated transcripts derived from a single copy gene". J. Immunol. 146 (1): 362–8. PMID1984448.
Lundwall AB, Wetsel RA, Kristensen T, et al. (1985). "Isolation and sequence analysis of a cDNA clone encoding the fifth complement component". J. Biol. Chem. 260 (4): 2108–12. PMID2579066.
Zuiderweg ER, Fesik SW (1989). "Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a". Biochemistry. 28 (6): 2387–91. doi:10.1021/bi00432a008. PMID2730871.
Zuiderweg ER, Nettesheim DG, Mollison KW, Carter GW (1989). "Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data". Biochemistry. 28 (1): 172–85. doi:10.1021/bi00427a025. PMID2784981.
Haefliger JA, Tschopp J, Vial N, Jenne DE (1989). "Complete primary structure and functional characterization of the sixth component of the human complement system. Identification of the C5b-binding domain in complement C6". J. Biol. Chem. 264 (30): 18041–51. PMID2808363.
Wetsel RA, Lemons RS, Le Beau MM, et al. (1988). "Molecular analysis of human complement component C5: localization of the structural gene to chromosome 9". Biochemistry. 27 (5): 1474–82. doi:10.1021/bi00405a012. PMID3365401.
Zuiderweg ER, Mollison KW, Henkin J, Carter GW (1988). "Sequence-specific assignments in the 1H NMR spectrum of the human inflammatory protein C5a". Biochemistry. 27 (10): 3568–80. doi:10.1021/bi00410a007. PMID3408713.
Stewart JL, Kolb WP, Sodetz JM (1987). "Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement". J. Immunol. 139 (6): 1960–4. PMID3624872.
Buhl AM, Osawa S, Johnson GL (1995). "Mitogen-activated protein kinase activation requires two signal inputs from the human anaphylatoxin C5a receptor". J. Biol. Chem. 270 (34): 19828–32. doi:10.1074/jbc.270.34.19828. PMID7649993.
Babkina IN, Seregin SV, Daniliuk NK, et al. (1995). "[Chemico-enzymatic synthesis, cloning and expression of a gene for an analog of human anaphylatoxin C5a]". Bioorg. Khim. 21 (5): 359–64. PMID7661861.
Wang X, Fleischer DT, Whitehead WT, et al. (1995). "Inherited human complement C5 deficiency. Nonsense mutations in exons 1 (Gln1 to Stop) and 36 (Arg1458 to Stop) and compound heterozygosity in three African-American families". J. Immunol. 154 (10): 5464–71. PMID7730648.
Süsal C, Kirschfink M, Kröpelin M, et al. (1994). "Complement activation by recombinant HIV-1 glycoprotein gp120". J. Immunol. 152 (12): 6028–34. PMID7911492.
Arribas J, Arizti P, Castaño JG (1994). "Antibodies against the C2 COOH-terminal region discriminate the active and latent forms of the multicatalytic proteinase complex". J. Biol. Chem. 269 (17): 12858–64. PMID8175701.
Süsal C, Kirschfink M, Kröpelin M, et al. (1996). "Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120". Blood. 87 (6): 2329–36. PMID8630395.
Ames RS, Li Y, Sarau HM, et al. (1996). "Molecular cloning and characterization of the human anaphylatoxin C3a receptor". J. Biol. Chem. 271 (34): 20231–4. doi:10.1074/jbc.271.34.20231. PMID8702752.
Fredslund F, Laursen NS, Roversi P, et al. (2008). "Structure of and influence of a tick complement inhibitor on human complement component 5". Nat Immunol. 9 (7): 753–60. doi:10.1038/ni.1625. PMID18536718.
